TG THERAPEUTICS, INC. — Director's Dealing 2023

Mar 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TG THERAPEUTICS, INC. (TGTX)
CIK: 0001001316
Period of Report: 2023-03-12

Reporting Person: WEISS MICHAEL S (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-12	COMMON STOCK	A	985000	—	Acquired	11973021	Direct

Footnotes

F1: Reflects a grant of restricted shares, which will vest and become non-forfeitable based on the Company's total shareholder return relative to the Nasdaq Biotechnology Index over a one-year to five-year period, provided that the Reporting Person remains an employee, director and/or consultant of the Company through each vesting date.

F2: Includes shares of restricted Common Stock, which vest over various time periods.